- Home
- NMM vs DNTH Comparison
NMM vs DNTH Comparison
Compare NMM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- DNTH
- Stock Information
- Founded
- NMM 2007
- DNTH 2015
- Country
- NMM Greece
- DNTH United States
- Employees
- NMM N/A
- DNTH N/A
- Industry
- NMM Marine Transportation
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- DNTH Health Care
- Exchange
- NMM Nasdaq
- DNTH Nasdaq
- Market Cap
- NMM 1.3B
- DNTH 1.5B
- IPO Year
- NMM 2007
- DNTH N/A
- Fundamental
- Price
- NMM $44.60
- DNTH $34.75
- Analyst Decision
- NMM
- DNTH Strong Buy
- Analyst Count
- NMM 0
- DNTH 10
- Target Price
- NMM N/A
- DNTH $66.38
- AVG Volume (30 Days)
- NMM 108.8K
- DNTH 754.7K
- Earning Date
- NMM 11-04-2025
- DNTH 11-06-2025
- Dividend Yield
- NMM 0.45%
- DNTH N/A
- EPS Growth
- NMM N/A
- DNTH N/A
- EPS
- NMM 10.24
- DNTH N/A
- Revenue
- NMM $1,305,026,000.00
- DNTH $4,854,000.00
- Revenue This Year
- NMM N/A
- DNTH N/A
- Revenue Next Year
- NMM $9.93
- DNTH N/A
- P/E Ratio
- NMM $4.38
- DNTH N/A
- Revenue Growth
- NMM N/A
- DNTH 17.87
- 52 Week Low
- NMM $28.37
- DNTH $13.37
- 52 Week High
- NMM $63.54
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- NMM 40.26
- DNTH 52.60
- Support Level
- NMM $43.39
- DNTH $33.96
- Resistance Level
- NMM $45.54
- DNTH $40.16
- Average True Range (ATR)
- NMM 1.05
- DNTH 2.05
- MACD
- NMM -0.47
- DNTH -0.96
- Stochastic Oscillator
- NMM 23.87
- DNTH 13.39
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.